Kaneka Eurogentec announces the successful production of 25g mRNA in one batch

Products & Services

Demonstrating mRNA production capabilities suitable for late clinical and commercial scales

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization (CDMO), announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer.

Successful large-scale mRNA production

Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of material in one batch that will be tested by the customer. This quantity is equivalent to 100,000’s to millions of doses of mRNA, potentially sufficient for late clinical and commercial uses. 

Ingrid Dheur, Vice President Biopharma Development at Kaneka Eurogentec stated, “This successful production confirms our ability to produce mRNA at large scale and with a quantity and purity level that exceeds the targets requested by the customer.”

Lieven Janssens, President and CEO at Kaneka Eurogentec added “The rapid growth in cell and gene therapy products is driving the need for plasmid DNA and mRNA production. Our existing pharma and biotech customers have already expressed the need for such large-scale manufacturing capabilities, and we have developed methods to respond to these needs. Additionally, we are currently in the planning stages for a 2nd manufacturing facility to further expand our GMP mRNA manufacturing offering”.

Learn More on IVT RNA Services

About mRNA

Messenger RNA (mRNA) is a molecule that encodes for a protein which will have a beneficial effect in patients. Rather than producing complex proteins, producing mRNA is a convenient way to deliver the protein as a precursor. The production of mRNA is much simpler than producing a recombinant protein and thus mRNA molecules have the advantage of enabling a shorter production time to clinic. For example, current mainstream therapies for the protection against COV-SARS-2 infections are based on mRNA and have been developed in record time. The success of these COVID-19 mRNA vaccines has opened the evaluation of mRNA for other infectious diseases, for example influenza or HIV, and the need for custom large-scale production of GMP mRNA.

  • _JDA1423
  • _JDA1472
  • _JDA3253
  • _JDA1423
  • _JDA1472
  • _JDA3253

Trending Now

We welcomed the Ambassador of Japan to Belgium at Kaneka Eurogentec

Previous post

A new website search fast, easy and accurate

Next post

Recommended for you

22-25 October 2024

ESGCT

Rome, Italy

Eurogentec exhibits at "ESGCT"

22-25 October 2024 @ Rome, Italy
Eurogentec will exhibit at the "European Society of Gene & Cell Therapy Annual Meeting "...
Continue Reading

Therapeutic oligos: promising types and the..

Products & Services

This article will explore the mechanisms behind some of the most promising types of therapeutic...
Continue Reading

Tips for Choosing the Right SYBR® Master Mix

Products & Services

When it comes to quantitative PCR (qPCR), choosing the right assay technology can significantly impact...
Continue Reading